References in periodicals archive ?
Immunohistochemically, tumour cells were strongly positive for dendritic cell markers CD21 and CD23 (Figure-4 and 5).
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
A drug such as Remicade (Ritindmab) which is widely used in treating oncology patients has a number of different activities; its likely the most important function of the drug is to link the Fc portion of Remicade to the patients Natural Killer cells and mediate Antibody Dependant Cell Cytotoxicity and Complement Dependant Cytotoxicity these activities are important in killing the cancer cells, Rituximab has also been shown to increases MHC II and adhesion molecules, it elicits shedding of CD23, it down regulates the B cell receptor and it induces apoptosis of CD20+ cells.
Immunohistochemistry revealed tumour cell expression of CD20, CD10, and immunonegative for CD3, CD5, CD23, and CD30.
Molecular blocking of CD23 supports its role in the pathogenesis of arthritis.
Lumiliximab is a chimeric monoclonal antibody directed against CD23 antigen, which is highly expressed on CLL cells but only minimally on other cells .
In lymphoma CD20 and CD79a (pan B-cell markers), CD3 and CD5 (pan T-cell markers), CD15 and CD30 (Hodgkin lymphoma marker), CD10, CD23 and EMA were applied.
Some lymphoproliferative disorders like CD23 negative chronic lymphocytic leukemia's, CD5 negative mantle cell lymphomas, CD5 positive follicular lymphomas, CD10 negative follicular lymphomas and CD5 positive splenic marginal zone lymphomas also exist and should always be considered in differential diagnosis in appropriate cases.
e, SmIgdim, CD5+, CD19+, CD20dim, CD23 ) in peripheral blood, bone marrow, lymphnodes and other lymphoid tissues.
Immunohhistochemical Marker Cell type CD45 CD21 CD23 CD35 SI00 CDla Langerin Fascin LCH LC (+) (-) (-) (-) (+) (+) (+) only + IDC (+) (-) (-) (-) (+) (-) (-) (+) Macrophage or (+) (-) (-) (-) (+/-) (-) (-) (+/-) histiocyte l/DDC (+) (-) (-) (-) (-/+) (-) (-) (+) pDC (-) (-) (-) (-) (-) (-) (-) (-) FDC (-) (+) (+) (+) (+/-) (-) (-) (+) FRC (+) (-) (-) (-) (-) (-) (-) Cell type Clusterin CD68 CD123 CD163 CD4 FXIIIa TCLI LC (-) (+) (-) (-) (+) (-) (-) IDC (-/+) (+/-) (-) (-) (+) (-) y Macrophage or (-) (+) (-) (+) (+) (-) (-) histiocyte l/DDC (-) (+) (-) (-) (+/-) (+) (-) pDC (-) (+) (+.
while they were negative to CD15, CD30, CD45RO, CD43, CD23, CD21, CK116, PLAP, ALK, HMB45, EMA, CD20, CD79a, Cyclin Di, lysosim, actin and desmin.
One of the recent Antibodies to be introduced to the company catalogue is CD23 Human Recombinant.
Acronyms browser ?
Full browser ?
- CD205 antigen
- CD206 antigen
- CD207 antigen
- CD207 antigen, langerin
- CD207 molecule, langerin, C-type lectin domain family 4, member K
- CD209 antigen
- CD209 antigen-like protein 1
- CD209 molecule
- CD220 antigen
- CD221 antigen
- CD222 antigen
- CD225 antigen
- CD23 antigen
- CD230 antigen
- CD242 antigen
- CD243 antigen
- CD246 antigen
- CD25 antigen
- CD256 antigen
- CD26 antigen
- CD280 antigen
- CD29 antigen
- CD292 antigen
- CD294 antigen
- CD298 antigen
- CD299 antigen